The Imcyse journey began when the founders discovered the ability of certain peptides to stimulate the immune system in a new way. After further investigation they invented new peptides, called ImotopesTM and showed these could induce a special type of T cell (cytolytic CD4+ T cell) that breaks the chain of events leading to severe autoimmune disease.
The carefully designed synthetic peptides, ImotopesTM, stimulate T cells to develop into a new phenotype which in turn can control the disease inflammatory processes and autoimmune attack. While many current therapies for autoimmune diseases trigger a general suppression of the immune system, this discovery allows the body’s own immune system to delete only the cells that drive abnormal immune attack but leave the rest of the immune system functioning normally. This stops tissue and organ damage and disease progression and can create a favorable environment for potential healing of the damaged organ.
Imcyse continues to develop the technology, optimizing and advancing both the platform and each program.
With clinical-stage assets in Type 1 diabetes and Multiple sclerosis and several pre-clinical programs in large and rare disease indications we have developed a diverse pipeline. We have entered into our first strategic partnership, with Pfizer, to advance the development of ImotopesTM to treat Rheumatoid arthritis (RA). We aim to continue to develop and commercialize our products both through partnership with Pharma and others to be developed ourselves.
subtitle
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
position
